Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FAAH | O00519 | 1/20 | 0.39 |
| ▸ | PTGS2 | P35354 | 4/20 | 0.34 |
| ▸ | PTGS1 | P23219 | 2/20 | 0.34 |
| ▸ | CAPN1 | P07384 | 2/20 | 0.33 |
| ▸ | HDAC3 | O15379 | 2/20 | 0.31 |
| ▸ | HDAC1 | Q13547 | 2/20 | 0.31 |
| ▸ | HDAC2 | Q92769 | 2/20 | 0.31 |
| ▸ | HPGD | P15428 | 1/20 | 0.31 |
| ▸ | TSHR | P16473 | 1/20 | 0.31 |
| ▸ | BCHE | P06276 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10119571 | 0.89 | CNR1 (0.36) | FAAHPTGS2PTGS1TSHRBCHE | |
| SCHEMBL20104867 | 0.86 | HPGD (0.39) | PTGS2PTGS1HPGD | |
| SCHEMBL20104906 | 0.85 | HPGD (0.42) | PTGS2PTGS1HPGD | |
| SCHEMBL20113579 | 0.82 | PTGS2 (0.35) | FAAHPTGS2PTGS1BCHE | |
| SCHEMBL13863668 | 0.81 | TSHR (0.41) | PTGS2PTGS1HDAC3HDAC1HDAC2 | |
| SCHEMBL13396641 | 0.81 | PTPN1 (0.45) | FAAHPTGS2PTGS1HDAC3HDAC1 | |
| SCHEMBL20104860 | 0.81 | ALDH1A1 (0.36) | PTGS2PTGS1 | |
| SCHEMBL18115163 | 0.80 | CA1 (0.33) | PTGS2PTGS1CAPN1 | |
| SCHEMBL13396744 | 0.80 | NOD1 (0.44) | — | |
| SCHEMBL398591 | 0.79 | PTGS2 (0.38) | PTGS2PTGS1TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10280138-B2 | Nitric oxide donating derivatives of fluprostenol | NICOX S.A. (FR) | 2019-05-07 | — | — | US | disclosed |
| US-20180118676-A1 | NITRIC OXIDE DONATING DERIVATIVES OF LATANOPROST FREE ACID | NICOX S.A. (FR) | 2018-05-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10280138-B2 | Nitric oxide donating derivatives of fluprostenol | PTGIS, NOS2, PTGIR | FAAH 650/4885PTGS2 9/4885PTGS1 6/4885 |
| US-20180118676-A1 | NITRIC OXIDE DONATING DERIVATIVES OF LATANOPROST FREE ACID | PTGIS, NOS2, NOS1 | FAAH 233/4885PTGS2 9/4885PTGS1 5/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.